NASDAQ : REVB

Revelation Biosciences, Inc. — Company profile

Healthcare · Biotechnology · United States

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Details

NameRevelation Biosciences, Inc.
SectorHealthcare
IndustryBiotechnology
Employees9
Founded2020
CeoJames Rolke
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS76135L8871
Cusip76135L887
Cik1810560
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
James M. RolkeChairman and Chief Executive Officer
Chester Stanley Zygmont IIIChief Financial Officer and Corporate Secretary
Sandra VedrickVice President of Human Resources and Investor Relations
Carol OdleSenior Director of Clinical Projects

Contact

Address4660 La Jolla Village Drive, Suite 100, San Diego, California 92122, United States
Phone650 800 3717
Websitehttps://www.revbiosciences.com